Home > Healthcare > Small Molecule Sterile Injectable Drugs Market

Small Molecule Sterile Injectable Drugs Market Size

Report ID: GMI9001
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Small Molecule Sterile Injectable Drugs Market Size

Small Molecule Sterile Injectable Drugs Market size was valued at around USD 154.6 billion in 2023 and is estimated to grow at 7.1% CAGR from 2024 to 2032, due to the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders.

Small Molecule Sterile Injectable Drugs Market

To get key market trends

Download Free Sample

According to the International Agency for Research on Cancer (IARC), in 2022, around 20 million new cancer cases were reported projecting to be over 35 million cases by 2050, marking a 77% increase from 2022. This escalating global cancer crisis necessitated precise, potent treatments that have created opportunities for small molecules due to their targeted mechanism of action, high bioavailability, and rapid onset of effect. Therefore, widespread adoption of small molecule drugs for the cancer along with other disease condition/disorder treatment regime will spur the market growth.

Small Molecule Sterile Injectable Drugs Market Report Attributes
Report Attribute	Details
Base Year:	2023
Small Molecule Sterile Injectable Drugs Market Size in 2023:	USD 154.6 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	7.1%
2032 Value Projection:	USD 289.3 Billion
Historical Data for:	2021 – 2023
No. of Pages:	180
Tables, Charts & Figures:	323
Segments covered:	Drug Type, Product Type, Route of Administration, Application, Distribution Channel, and Region
Growth Drivers:	Rising prevalence of chronic diseases Rising demand for personalised and targeted therapies Growing R&D investment accelerated activities Advancement in drug delivery technology
Pitfalls & Challenges:	High cost of development and manufacturing Stringent regulatory requirements

Learn more about the key segments shaping this market

Download Free Sample

Small molecule sterile injectable drugs are pharmaceutical compounds consisting of low molecular weight molecules that are administered via injection and manufactured under sterile conditions to ensure purity and safety. These drugs typically exhibit rapid absorption and distribution in the body due to their small size, marking them as an effective treatment of various diseases and conditions.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Small molecule sterile injectable drugs industry size recorded USD 154.6 billion in 2023 and is expected to register 7.1% CAGR from 2024 to 2032, due to the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders.

The chemotherapy agents segment in the market is estimated to accumulate USD 71.4 billion by 2032, owing to the high prevalence of cancer and the ongoing demand for effective chemotherapy options.

North America small molecule sterile injectable drugs industry is expected to expand at 6.9% CAGR from 2024 to 2032, on account of the robust healthcare infrastructure, high prevalence of chronic diseases, and a favorable regulatory environment.

AbbVie Inc., Amgen Inc., AstraZeneca Plc., BioCryst Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Fresenius Kabi USA, Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major small molecule sterile injectable drugs companies worldwide.